$2.68
-0.12 (-4.29%)
Open$2.80
Previous Close$2.80
Day High$2.86
Day Low$2.65
52W High$7.13
52W Low$1.12
Volume—
Avg Volume234.7K
Market Cap175.38M
P/E Ratio—
EPS$-0.59
SectorBiotechnology
Analyst Ratings
Strong Buy
7 analysts
Price Target
+383.6% upside
Current
$2.68
$2.68
Target
$12.96
$12.96
$9.51
$12.96 avg
$17.52
Key Financials
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 42.71M | 37.98M | 43.70M |
| Net Income | -4,071,906 | -4,331,190 | -4,441,576 |
| Profit Margin | -9.5% | -11.4% | -10.2% |
| EBITDA | -6,278,520 | -5,337,134 | -5,924,921 |
| Free Cash Flow | -4,174,488 | -3,744,064 | -5,531,991 |
| Rev Growth | +12.9% | +2.3% | +21.5% |
| Debt/Equity | 0.88 | 1.10 | 1.06 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $214.98 | -1.15% | 166.6 | 397.77B |
| AMGN | Amgen Inc | $353.28 | +0.41% | 24.7 | 190.40B |
| GILD | Gilead Sciences Inc | $140.30 | +0.67% | 19.6 | 166.66B |
| VRTX | Vertex Pharmaceuticals Inc | $447.26 | +0.16% | 29.1 | 114.87B |
| REGN | Regeneron Pharmaceuticals | $777.25 | +0.60% | 17.9 | 80.50B |
| ALNY | Alnylam Pharmaceuticals Inc | $328.73 | -0.65% | 139.7 | 43.84B |